Atlas Trials

A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers

Clinical trial NCT03567642 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03567642
Sponsor
Memorial Sloan Kettering Cancer Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Lung Cancer
Start date
2018-06-12
Primary completion
2027-06-01
Enrollment
11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.